Update of intravitreal steroids for the treatment of diabetic macular edema

Francesco Bandello, Chiara Preziosa, Giuseppe Querques, Rosangela Lattanzio

Research output: Contribution to journalArticlepeer-review


Diabetic macular edema is considered the most important factor related to visual impairment in patients with diabetic retinopathy. Together with the use of grid and focal laser photocoagulation, today the intravitreal administration of pharmacotherapies represents the standard of care for the treatment of this complication: anti-vascular endothelium growth factor agents and steroids are the drugs currently used for this aim. Differently from laser therapy, which prevents visual deterioration, the intravitreal approach allows the promotion of visual recovery. However, the intravitreal injections require to be repeated with high frequency, and this carries the risk of drug- and procedure-related adverse effects.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalOphthalmic Research
Issue number2
Publication statusPublished - Apr 14 2014


  • Dexamethasone implant
  • Diabetic macular edema
  • Fluocinolone acetonide
  • Intravitreal pharmacotherapies
  • Steroids
  • Triamcinolone acetonide

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)


Dive into the research topics of 'Update of intravitreal steroids for the treatment of diabetic macular edema'. Together they form a unique fingerprint.

Cite this